Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03518723
Other study ID # NLPRT-RCT
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 16, 2018
Est. completion date March 1, 2023

Study information

Verified date May 2024
Source Umeå University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aims at improving the knowledge about resistance training for people with COPD. Resistance training is an important part of pulmonary rehabilitation when the goal is to improve muscular endurance and strength. The study will evaluate the effects and the feasibility of two resistance training programs for people with COPD using a parallel group design. One program will include a larger day-to-day variation (i.e. non-linear periodization) and the progression will be guided by ratings of dyspnea, muscle fatigue, and exertion. The other program will follow the established guidelines for resistance training for people with COPD. The programs will be evaluated for effects regarding muscular endurance, strength, intramuscular adaptions, functional preformance, dyspnea, and health related quality of life. The programs will also be evaluated for feasibility regarding the duration of training sessions, attendance rates, adverse events, and participant satisfaction. The hypothesis is that the non-linear periodization group will have superior effects and that feasibility aspects will be similar between groups.


Recruitment information / eligibility

Status Completed
Enrollment 57
Est. completion date March 1, 2023
Est. primary completion date March 1, 2023
Accepts healthy volunteers No
Gender All
Age group 40 Years to 89 Years
Eligibility Inclusion Criteria: - FEV1/FVC ratio < 70% postbronchodilator - FEV1 <80% of the predicted normal value postbronchodilator Exclusion Criteria: - Clinical evidence of asthma, cardiovascular diseases, and/or neuromuscular diseases that are unstable and/or that may contribute to exercise limitation - Other contraindications to exercise - Currently participating in a structured exercise or pulmonary rehabilitation program or been involved in pulmonary rehabilitation in the past 6 months - Experienced a COPD exacerbation and/or change in medication dosage/frequency in the past 6 weeks

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Non-linear Periodized Resistance Training
8 week non-linear periodized resistance training intervention, 3 sessions per week, 60 minutes per session
Resistance training
8 week resistance training intervention, 3 sessions per week, 60 minutes per session

Locations

Country Name City State
Canada Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec Québec City
Netherlands Merem Pulmonary Rehabilitation Centre Hilversum
Sweden Umeå University Umeå

Sponsors (4)

Lead Sponsor Collaborator
Umeå University Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec, Merem Pulmonary Rehabilitation Centre, Radboud University Medical Center

Countries where clinical trial is conducted

Canada,  Netherlands,  Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline dynamic maximal endurance at week 9 Maximal limb muscle endurance measured using resistance training machines or free weights. Reported as the number of repetitions at 45% of the baseline one repetition maximum. Baseline and week 9
Primary Change from baseline dynamic maximal strength at week 9 Maximal limb muscle strength measured using resistance training machines or free weights. Reported as one repetition max in kg. Baseline and week 9
Secondary Change from baseline static maximal endurance at week 9 Maximal limb muscle endurance measured using a computerized dynamometer or strain gauge. Reported in seconds maintaining 60% of the isometric maximal voluntary contraction. Baseline and week 9
Secondary Change from baseline static maximal strength at week 9 Maximal limb muscle strength measured using a computerized dynamometer or strain gauge. Reported in Nm Baseline and week 9
Secondary Change from baseline unsupported upper limb test (UULEX) at week 9 The UULEX is a progressive test where the participants will be asked to a raise plastic bar from the hip to the UULEX eight-level chart with a cadence of 30 movements per minute. If a patient reaches the highest level, the plastic bar will be replaced by a heavier one every minute. There are five different bar weights (0.2, 0.5, 1, 1.5, 2 Kg) and participants will continue on the highest level until symptom limitation. Results are reported in seconds. Baseline and week 9
Secondary Change from baseline endurance shuttle walk test (ESWT) at week 9 The ESWT is a derivative of the Incremental shuttle walk test (ISWT), where patients walk for as long as possible at a predetermined percentage of maximum walking performance as assessed by the ISWT on a 10 meter course. Reported in seconds to termination of the test or total meters walked. Baseline and week 9
Secondary Change from baseline 60 seconds sit to stand test (60STS) at week 9 During the 60STS, participants will be instructed to fully stand up and sit down as fast as possible, as many times as possible within 60 seconds. Arms will be held fold across the chest with feet remaining in full contact with the floor. Reported as the number of repetitions performed within 60 seconds. Baseline and week 9
Secondary Change From Baseline Chronic Respiratory Questionnaire Self-Administered Standardized Format (CRQ-SAS) Total Scores at week 9 The CRQ-SAS is a self-administered questionnaire which consist of 20 items across four domains: dyspnea (5 items), fatigue (4 items), emotional function (7 items), and mastery (4 items). Participants rates their experience on a 7-point scale in response to each item ranging from 1 (maximum impairment) to 7 (no impairment). Individual items are equally weighted, and total score ranges from 20 to 140 (20 maximum impairment, 140 no impairment). Baseline and week 9
Secondary Change From Baseline Chronic Respiratory Questionnaire Self-Administered Standardized Format (CRQ-SAS) dyspnea Domain Scores at week 9 Domain scores are calculated as the mean of all items (5) within the dyspnea domain. Participants rates their experience on a 7-point scale in response to each item ranging from 1 (maximum impairment) to 7 (no impairment). Individual items are equally weighted, and total score ranges from 7 to 35 (7 maximum dyspnea, 35 no dyspnea). Baseline and week 9
Secondary Number of responders The total amount of responders i.e. defined as a response over the known minimal detectable change/or minimal important difference for included test(s) will be determined and compared. Week 9
Secondary Attendance rate Attendance rate will be evaluated by calculating the number of attended sessions divided by total number of sessions for each participant Week 1 up to 8
Secondary Duration of exercise sessions Mean time in minutes of exercise sessions Week 1 up to 8
Secondary Satisfaction rate Participant satisfaction with the exercise regimens will be recorded by adapting an existing patient satisfaction questionnaire. Participants rate their satisfaction on 7 items each with a 5 point likert scale. Results using the total score (0-35, higher score indicating higher satisfaction). Week 9
Secondary Proportion of drop-outs Proportion of participants that don't complete the intervention Week 9
Secondary Adverse Events rate Occurrence of any adverse events. An adverse event rate will be calculated for each patient as the total number of sessions during which any adverse events occurred divided by the total number of attended sessions. Week 1 up to 8
Secondary Adverse Events stratified by severity The severity of the adverse events will be assessed and rated into four different categories: 1) minor and temporary, 2) serious symptoms (potential risk of severe injury or life threatening), 3) manifest injury or disease, and 4) death. Presented in factual numbers for each group. Week 1 up to 8
Secondary Change from baseline muscle fiber size at week 9 The tissue sample obtained from the vastus lateralis muscle will be examined with morphometric analyses to determine cross-sectional fiber area. Reported in square micrometers. Baseline and week 9
Secondary Change from baseline proportion of slow and fast subtypes of contractile myosin heavy chain isoforms in fibers at week 9 The tissue sample obtained from the vastus lateralis muscle will be examined with immunohistochemistry techniques to categorize fiber types. Baseline and week 9
Secondary Change from baseline oxidative (citrate synthase (CS), EC 4.1.3.7) enzyme activities at week 9 The tissue sample obtained from the vastus lateralis muscle will be examined to demonstrate enzyme activities. Reported in micromol/min/g tissue.
[Time Frame: Baseline and week 9] The tissue sample obtained from the vastus lateralis muscle will be examined by histochemistry to demonstrate enzyme activities. Reported in micromol/min/g tissue.
Baseline and week 9
Secondary Change from baseline glycolytic (lactate dehydrogenase (LDH), EC 1.1.1.27) enzyme activities at week 9 The tissue sample obtained from the vastus lateralis muscle will be examined to demonstrate enzyme activities. Reported in micromol/min/g tissue. Baseline and week 9
Secondary Change from baseline capillarization (capillary density) at week 9 The tissue sample obtained from the vastus lateralis muscle will be examined with morphometric analysis to determine capillary density, estimated as the total number of capillaries per millimeter squared muscle cross-section. Baseline and week 9
Secondary Change from baseline capillarization (capillaries to fiber) at week 9 The tissue sample obtained from the vastus lateralis muscle will be examined with morphometric analysis to determine the number of capillaries around fibers including all capillaries in contact with each muscle fiber. Baseline and week 9
Secondary Change from baseline capillarization (capillaries relative to fiber area) at week 9 The tissue sample obtained from the vastus lateralis muscle will be examined with morphometric analysis to determine the number of capillaries around each fiber relative to its cross-sectional area. Baseline and week 9
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03572335 - Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
Recruiting NCT06088485 - The Effect of Bone Mineral Density in Patients With Adult Cystic Fibrosis
Terminated NCT03309358 - A Study of the Safety and Tolerability of Inhaled SNSP113 in Healthy Subjects and Subjects With Stable Cystic Fibrosis Phase 1
Active, not recruiting NCT02504697 - DECAMP-2: Screening of Patients With Early Stage Lung Cancer or at High Risk for Developing Lung Cancer
Completed NCT01443845 - Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS) Phase 4
Terminated NCT00524095 - Bronchiectasis in Chronic Obstructive Pulmonary Disease (COPD) Patients: Role of Prophylaxis Phase 2
Completed NCT00210249 - Development of an Evaluation Method of Elderly Condition in Patient Receiving Chemotherapy Treatment
Completed NCT00023114 - p450 Mediated Lung Toxicity N/A
Recruiting NCT06056882 - Simultaneous CLE Guided Crybiopsy in Patients With Pulmonary Nodules
Completed NCT03994848 - Incentive Spirometry Prehabilitation Study N/A
Completed NCT00366509 - Role of Helicobacter Pylori and Its Toxins in Lung and Digestive System Diseases
Withdrawn NCT05100160 - Gabapentin for the Reduction of Opiate Use Following Pulmonary Resection (GROUP Trial) Phase 3
Completed NCT03229473 - Fall Risk Assessment in COPD
Recruiting NCT04767074 - A Non-pharmacological Cough Control Therapy N/A
Not yet recruiting NCT03899298 - Safety and Clinical Outcomes With Amniotic and Umbilical Cord Tissue Therapy for Numerous Medical Conditions Phase 1
Completed NCT04996693 - On Dose Efficiency of Modern CT-scanners in Chest Scans N/A
Recruiting NCT04996173 - Cryospray Therapy Versus Standard of Care for Benign Airway Stenosis (CryoStasis) N/A
Completed NCT04601545 - The Virtual Reality Therapy as a Pulmonary Rehabilitation Supporting Method N/A
Recruiting NCT03937583 - Screening for Cancer in Patients With Unprovoked VTE Phase 4
Recruiting NCT02862418 - Imaging of Lungs With a New Type of Magnetic Resonance Imaging (MRI) Called UTE (Ultrashort Echo Time)